Cardionovum® Begins In Vivo Testing of Its Paclitaxel-Coated Drug-Eluting Balloon (DEB)
“We are well-positioned to be a dominant competitor in the emerging market for drug-eluting balloons (DEBs) as a first-line therapy for many patients, including those with critical limb ischemia (CLI) and those who must undergo repeated interventions, such as diabetics.”
“We are well-positioned to be a dominant competitor in the emerging market for drug-eluting balloons (DEBs) as a first-line therapy for many patients, including those with critical limb ischemia (CLI) and those who must undergo repeated interventions, such as diabetics.” Dr. Michael Orlowski, CEO, one of the pioneers of DEB technologies.
Cardionovum GmbH announced today that it has initiated in vivo testing of its second drug-eluting balloon (DEB) RESTORE™. The Company is currently marketing a line of CE-marked paclitaxel-coated DEBs for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.
The RESTORE family of DEBs is novel because of its unique, highly intense and “EXPRESS” drug-release platform. RESTORE was developed for the clinically efficient and successful treatment of patients who come back for repeat anti-proliferative treatment of restenosis. RESTORE’s ‘PTX’ coating ensures a biocompatible drug transfer into the arterial tissue under avoidance of micro emboli, which are often observed after application of other DEBs, as observed by Renu Virmani, M.D., CV Path Institute, USA. “RESTORE complements our current DEB product portfolio with additional therapeutic capacities,” said Michael Orlowski, Ph.D., CEO of Cardionovum.
“Our core competence is in medical coating technologies. Our mission is to develop an entirely new paradigm for the safest and clinically most effective local drug delivery to the arterial lesion site,” added Dr. Orlowski. “ We believe that our novel approach to drug-coating is superior to existing products on the market, as we do not use plasticizer, nor uncontrollable toxic drug excipients, giving us a potentially dominant position in the emerging market for DEBs as first-line therapy for a wide variety of patients in need of coronary and peripheral vascular interventions.”
Based on its breakthrough and proprietary ‘PTX’ Gradient and High Intensity “EXPRESS” balloon-coated drug transfer technology, Cardionovum has developed and is commercializing in Europe clinically advanced medical therapies that are designed to improve upon current patient treatment standards for drug-eluting stents and drug-eluting balloons to treat coronary and peripheral artery disease.
NOTICE: Cardionovum’s products are not available for sale in the United States.